DE602005022764D1 - Piperidin- und azetidinderivate als glyt1-inhibitoren - Google Patents
Piperidin- und azetidinderivate als glyt1-inhibitorenInfo
- Publication number
- DE602005022764D1 DE602005022764D1 DE602005022764T DE602005022764T DE602005022764D1 DE 602005022764 D1 DE602005022764 D1 DE 602005022764D1 DE 602005022764 T DE602005022764 T DE 602005022764T DE 602005022764 T DE602005022764 T DE 602005022764T DE 602005022764 D1 DE602005022764 D1 DE 602005022764D1
- Authority
- DE
- Germany
- Prior art keywords
- piperidine
- glyt1 inhibitors
- azetidine derivatives
- heteroaryl
- glyt1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical class C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0427987A GB0427987D0 (en) | 2004-12-21 | 2004-12-21 | Therapeutic agents |
| GB0427989A GB0427989D0 (en) | 2004-12-21 | 2004-12-21 | Heteroaromatic compounds |
| PCT/GB2005/050258 WO2006067529A1 (en) | 2004-12-21 | 2005-12-21 | Piperidine and azetidine derivatives as glyt1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005022764D1 true DE602005022764D1 (de) | 2010-09-16 |
Family
ID=35949843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005022764T Active DE602005022764D1 (de) | 2004-12-21 | 2005-12-21 | Piperidin- und azetidinderivate als glyt1-inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7655644B2 (de) |
| EP (1) | EP1831201B1 (de) |
| JP (1) | JP5055493B2 (de) |
| AT (1) | ATE476431T1 (de) |
| AU (1) | AU2005317846B2 (de) |
| CA (1) | CA2592345C (de) |
| DE (1) | DE602005022764D1 (de) |
| WO (1) | WO2006067529A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070105902A1 (en) * | 2003-11-12 | 2007-05-10 | Lindsley Craig W | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
| EP1729772B8 (de) * | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl-piperidin-glycin-transporterhemmer |
| AU2005243192A1 (en) * | 2004-04-29 | 2005-11-24 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
| WO2005107469A2 (en) * | 2004-05-05 | 2005-11-17 | Merck & Co., Inc. | Morpholinyl piperidine glycine transporter inhibitors |
| RU2387644C2 (ru) * | 2004-09-30 | 2010-04-27 | Мерк Энд Ко., Инк. | Циклопропилпиперидиновые ингибиторы транспортера глицина |
| US7655644B2 (en) | 2004-12-21 | 2010-02-02 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
| EP1893566B1 (de) * | 2005-06-06 | 2013-02-13 | Merck Sharp & Dohme Ltd. | Cyclohexansulfonylderivate als glyt1-hemmer zur behandlung von schizophrenie |
| US8163956B2 (en) | 2005-06-13 | 2012-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of GLYT1 transporters |
| EP1942893A4 (de) * | 2005-10-28 | 2011-10-12 | Merck Sharp & Dohme | Piperidin-glycin-transporter-hemmer |
| JP2012514006A (ja) * | 2008-12-29 | 2012-06-21 | バンダービルト ユニバーシティ | ３．１．０二環式ＧｌｙＴ１阻害剤ならびにその作製および使用の方法 |
| EP2403337A4 (de) * | 2009-03-03 | 2012-08-15 | Univ Vanderbilt | Alkylsulfonyl-2,3-dihydrospiro[inden-1,4'-piperidin]-analoge als glyt1-hemmer, verfahren zu ihrer herstellung sowie ihre verwendung zur behandlung psychiatrischer erkrankungen |
| EP2413701A4 (de) * | 2009-03-31 | 2012-10-03 | Univ Vanderbilt | Sulfonyl-azetidin-3-yl-methylamin-amidanaloga als glyt1-hemmer, verfahren zu ihrer herstellung sowie ihre verwendung zur behandlung psychiatrischer erkrankungen |
| US8436019B2 (en) * | 2009-03-31 | 2013-05-07 | Vanderbilt University | Sulfonyl-piperidin-4-yl methylamine amide analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders |
| US8883839B2 (en) * | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| TWI598325B (zh) * | 2012-10-12 | 2017-09-11 | Ｈ 朗德貝克公司 | 苯甲醯胺類 |
| TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2219924C2 (ru) * | 1998-04-14 | 2003-12-27 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения нейропсихиатрических расстройств |
| EP1377293B1 (de) * | 2001-04-12 | 2010-03-10 | Pharmacopeia, LLC | Arly und diaryl piperidinderivate verwendbar als mch-hemmer |
| ATE446286T1 (de) * | 2001-11-26 | 2009-11-15 | Schering Corp | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US20070105902A1 (en) | 2003-11-12 | 2007-05-10 | Lindsley Craig W | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
| CA2556589A1 (en) * | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| EP1729772B8 (de) * | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl-piperidin-glycin-transporterhemmer |
| AU2005243192A1 (en) | 2004-04-29 | 2005-11-24 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
| WO2005107469A2 (en) | 2004-05-05 | 2005-11-17 | Merck & Co., Inc. | Morpholinyl piperidine glycine transporter inhibitors |
| RU2387644C2 (ru) * | 2004-09-30 | 2010-04-27 | Мерк Энд Ко., Инк. | Циклопропилпиперидиновые ингибиторы транспортера глицина |
| US7655644B2 (en) | 2004-12-21 | 2010-02-02 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
| EP1893566B1 (de) | 2005-06-06 | 2013-02-13 | Merck Sharp & Dohme Ltd. | Cyclohexansulfonylderivate als glyt1-hemmer zur behandlung von schizophrenie |
-
2005
- 2005-12-21 US US11/792,111 patent/US7655644B2/en active Active
- 2005-12-21 CA CA2592345A patent/CA2592345C/en not_active Expired - Fee Related
- 2005-12-21 AT AT05821636T patent/ATE476431T1/de not_active IP Right Cessation
- 2005-12-21 AU AU2005317846A patent/AU2005317846B2/en not_active Ceased
- 2005-12-21 WO PCT/GB2005/050258 patent/WO2006067529A1/en active Application Filing
- 2005-12-21 EP EP05821636A patent/EP1831201B1/de active Active
- 2005-12-21 DE DE602005022764T patent/DE602005022764D1/de active Active
- 2005-12-21 JP JP2007547679A patent/JP5055493B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1831201B1 (de) | 2010-08-04 |
| JP5055493B2 (ja) | 2012-10-24 |
| EP1831201A1 (de) | 2007-09-12 |
| CA2592345A1 (en) | 2006-06-29 |
| ATE476431T1 (de) | 2010-08-15 |
| AU2005317846B2 (en) | 2011-12-08 |
| CA2592345C (en) | 2013-09-24 |
| AU2005317846A1 (en) | 2006-06-29 |
| JP2008524316A (ja) | 2008-07-10 |
| US20080090796A1 (en) | 2008-04-17 |
| WO2006067529A1 (en) | 2006-06-29 |
| US7655644B2 (en) | 2010-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
| NO20070555L (no) | Kinazolinonderivater som parp-inhibitorer | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| NO20070529L (no) | Kinazolindionderivater som parp-inhibitorer | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| NO20053794L (no) | N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine. | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| SE0401971D0 (sv) | Piperidne derivatives | |
| NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
| NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| NO20091892L (no) | Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre | |
| NO20085087L (no) | Nye heterocykliske forbindelser | |
| ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
| NO20081001L (no) | Derivater av karboksamid som antagonister for muskarinisk reseptor | |
| DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| SE0301701D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| WO2007020411A8 (en) | Amide derivatives | |
| SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |